Neuraxpharm
Neuraxpharm is a leading European pharmaceutical company dedicated to advancing CNS (central nervous system) treatments through innovation, research, and responsible business practices. With a pipeline of over 25 projects focused on CNS, the company emphasizes patient-centric solutions, sustainability, and a strong corporate culture rooted in ethics, diversity, and environmental responsibility. Neuraxpharm aims to improve the quality of life for patients worldwide by providing high-quality, safe, and effective therapies, while fostering a sustainable future and a positive societal impact.
Industries
Nr. of Employees
Very Large (1000+)
Neuraxpharm
Elisabeth-Selbert-Straße, 23, 40764 Langenfeld, Germany
Patents
Process for the manufacture of R-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride
US-10800748-B2
View Details
Process for the manufacture of R-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride
US-10800748-B2
View DetailsProducts
Epilepsy self-management mobile application
Patient-facing mobile application for seizure management that captures structured event logs and clinical history, generates visual longitudinal reports, enables media uploads and sharing with healthcare professionals, and provides emergency alert functionality.
Medical cannabis treatment support mobile application
Patient mobile application to download clinician-prescribed treatment plans, report symptoms, locate pharmacies, track appointments and upload treatment-related documents to support adherence and clinical follow-up for cannabinoid-based therapies.
CNS therapeutic product portfolio
A range of central nervous system therapeutics including generics, differentiated formulations, biologic therapies, orphan indication treatments and selected cannabinoid-based products for clinical use.
CNS candidate development pipeline (>25 projects)
Active development portfolio of multiple CNS programs across neurology and psychiatry, including early- and mid-stage small molecule and biologic candidates available for co-development or licensing.
Epilepsy self-management mobile application
Patient-facing mobile application for seizure management that captures structured event logs and clinical history, generates visual longitudinal reports, enables media uploads and sharing with healthcare professionals, and provides emergency alert functionality.
Medical cannabis treatment support mobile application
Patient mobile application to download clinician-prescribed treatment plans, report symptoms, locate pharmacies, track appointments and upload treatment-related documents to support adherence and clinical follow-up for cannabinoid-based therapies.
CNS therapeutic product portfolio
A range of central nervous system therapeutics including generics, differentiated formulations, biologic therapies, orphan indication treatments and selected cannabinoid-based products for clinical use.
CNS candidate development pipeline (>25 projects)
Active development portfolio of multiple CNS programs across neurology and psychiatry, including early- and mid-stage small molecule and biologic candidates available for co-development or licensing.
Services
Collaborative models to support product development, regulatory and commercial strategy, market access and distribution across European markets.
National market access strategy development and execution to optimize payer engagement and reimbursement for CNS products in European countries.
Co-development, licensing and business development support for advancing CNS pipeline projects, including early-stage R&D, candidate selection and in‑licensing opportunities.
Management of in‑house manufacturing capabilities and external contract manufacturing partners to support production, quality and supply chains.
Program leadership and medical/scientific support for clinical trial design, safety oversight and post-marketing medical affairs activities.
Collaborative models to support product development, regulatory and commercial strategy, market access and distribution across European markets.
National market access strategy development and execution to optimize payer engagement and reimbursement for CNS products in European countries.
Co-development, licensing and business development support for advancing CNS pipeline projects, including early-stage R&D, candidate selection and in‑licensing opportunities.
Management of in‑house manufacturing capabilities and external contract manufacturing partners to support production, quality and supply chains.
Program leadership and medical/scientific support for clinical trial design, safety oversight and post-marketing medical affairs activities.
Expertise Areas
- Central nervous system therapeutics
- Neurology and psychiatry drug development
- Clinical research and medical affairs
- Biologics development and pipeline management
Key Technologies
- Mobile health applications
- Patient-reported outcome (PRO) capture
- Geolocation-enabled emergency notification
- Longitudinal clinical data visualization and reporting
News & Updates
This World MS Day, a story reflecting resilience and creativity in the MS community is shared.
The new website highlights how Neuraxpharm is transforming the future of CNS care in Europe and beyond.
Campaign to educate and empower epilepsy patients, caregivers, and healthcare professionals.
Overview of the company's mission and dedication to improving lives affected by neurological and psychiatric disorders.
Vikas brings over 25 years of healthcare and clinical research experience.
Recognized among the top 15% of companies assessed globally for sustainability management.
This World MS Day, a story reflecting resilience and creativity in the MS community is shared.
The new website highlights how Neuraxpharm is transforming the future of CNS care in Europe and beyond.
Campaign to educate and empower epilepsy patients, caregivers, and healthcare professionals.
Overview of the company's mission and dedication to improving lives affected by neurological and psychiatric disorders.
Vikas brings over 25 years of healthcare and clinical research experience.
Recognized among the top 15% of companies assessed globally for sustainability management.